Literature DB >> 19539542

Implantable cardioverter-defibrillator prescription in the elderly.

Andrew E Epstein1, G Neal Kay, Vance J Plumb, H Thomas McElderry, Harish Doppalapudi, Takumi Yamada, Jeff Shafiroff, Zaffer A Syed, Sergio Shkurovich.   

Abstract

BACKGROUND: Because sudden cardiac death increases with age, implantable cardioverter-defibrillators (ICDs) might greatly benefit the elderly. However, elderly patients are underrepresented in clinical trials, and comorbid conditions may attenuate benefit.
OBJECTIVE: The purpose of this study was to examine ICD prescription in the elderly.
METHODS: The ages, indications, and implanted ICD type of patients enrolled in the Advancements in ICD Therapy (ACT) Registry were compared to those from the National Cardiovascular Data Registry (NCDR).
RESULTS: The ACT Registry included 4,566 patients who underwent first ICD or cardiac resynchronization therapy ICD (CRT-D) implantation. Among these patients, 2.6% were 18-39 years old, 8.6% were 40-49 years, 20.1% were 50-59 years, 27.6% were 60-69 years, 29.0% were 70-79 years, and 12.0% were >or=80 years. In the six age groups, 82.5%, 79.4%, 77.3%, 80.1%, 77.7%, and 74.6% received devices for primary prevention, and single-chamber ICDs were implanted in 41.4%, 42.8%, 38.7%, 33.8%, 25.2%, and 28.1%, respectively (P <.0001). Two-year mortality rates increased incrementally from 5.80% to 17.80% in the six groups (P <.05). Noncardiac death was more common in older than in younger patients. Among patients >or=80 years old receiving a CRT-D, 78% had QRS duration and New York Heart Association class that met accepted implantation criteria. Age distribution, indication, and type of device were similar in the ACT Registry and in 74,476 patients in the NCDR.
CONCLUSION: More than 40% of new ICDs and CRT-Ds are implanted in patients >70 years old and more than 10% in patients >or=80 years old. A significant proportion of those receiving a CRT-D did not fulfill accepted criteria for implantation. Noncardiac death occurred more frequently in older patients, but cardiac death rates were similar.

Entities:  

Mesh:

Year:  2009        PMID: 19539542     DOI: 10.1016/j.hrthm.2009.04.010

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  35 in total

1.  Geographic variation in implantable cardioverter-defibrillator use and heart failure survival.

Authors:  Andrew J Epstein; Daniel Polsky; Feifei Yang; Lin Yang; Peter W Groeneveld
Journal:  Med Care       Date:  2012-01       Impact factor: 2.983

2.  Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention.

Authors:  Joshua R Silverstein; Demosthenes G Katritsis; Mark E Josephson
Journal:  Arrhythm Electrophysiol Rev       Date:  2012-09

3.  Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.

Authors:  Paul L Hess; Sana M Al-Khatib; Joo Y Han; Rex Edwards; Gust H Bardy; J Thomas Bigger; Alfred Buxton; Riccardo Cappato; Paul Dorian; Al Hallstrom; Alan H Kadish; Peter J Kudenchuk; Kerry L Lee; Daniel B Mark; Arthur J Moss; Richard Steinman; Lurdes Y T Inoue; Gillian Sanders
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-02-10

4.  The impact of age on clinical outcomes following cardiac resynchronisation therapy.

Authors:  K Guha; D Konstantinou; L Mantziari; B N Modi; B Chandrasekaran; Z Khalique; T McDonagh; R Sharma
Journal:  J Interv Card Electrophysiol       Date:  2013-11-29       Impact factor: 1.900

5.  Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association.

Authors:  Jerome L Fleg; Daniel E Forman; Kathy Berra; Vera Bittner; James A Blumenthal; Michael A Chen; Susan Cheng; Dalane W Kitzman; Mathew S Maurer; Michael W Rich; Win-Kuang Shen; Mark A Williams; Susan J Zieman
Journal:  Circulation       Date:  2013-10-28       Impact factor: 29.690

6.  Nursing Home Use After Implantable Cardioverter-Defibrillator Implantation in Older Adults: Results from the National Cardiovascular Data Registry.

Authors:  Daniel B Kramer; Matthew R Reynolds; Sharon-Lise Normand; Craig S Parzynski; John A Spertus; Vincent Mor; Susan L Mitchell
Journal:  J Am Geriatr Soc       Date:  2016-11-07       Impact factor: 5.562

7.  Subject of the year: who are we missing, who are we overtreating, and who is best served? Refining the prescription of implantable cardioverter-defibrillator therapy.

Authors:  Andrew E Epstein
Journal:  J Interv Card Electrophysiol       Date:  2009-11       Impact factor: 1.900

8.  Facility-Level Variation and Clinical Outcomes in Use of Cardiac Resynchronization Therapy With and Without an Implantable Cardioverter-Defibrillator.

Authors:  Daniel B Kramer; Sharon-Lise T Normand; Rita Volya; Laura A Hatfield
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-12

Review 9.  Resynchronization: considering device-based cardiac therapy in older adults.

Authors:  Daniel B Kramer; Matthew R Reynolds; Susan L Mitchell
Journal:  J Am Geriatr Soc       Date:  2013-03-21       Impact factor: 5.562

10.  Decision-Making Experiences of Patients with Implantable Cardioverter Defibrillators.

Authors:  Ariel R Green; Amy Jenkins; Frederick A Masoudi; David J Magid; Jean S Kutner; Bruce Leff; Daniel D Matlock
Journal:  Pacing Clin Electrophysiol       Date:  2016-09-22       Impact factor: 1.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.